Skip to Content

AngioGenex Inc

Rating as of

Company Profile

Business Description

AngioGenex Inc is a United States-based biopharmaceutical company. It is dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration. Its lead drug candidates include AGX51 and several other proprietary small molecules that have shown specific activity in various animal models of various cancers and macular degeneration. Further, it also focuses on developing Id-inhibitor drugs to treat cancer and macular degeneration. Geographically, the activities are carried out through the region of the United States.

425 Madison Avenue, Suite 902
New York, NY, 10017
T +1 347 468-6799
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2019
Fiscal Year End Dec 31, 2019
Stock Type Slow Growth